Remdesivir has been found to have provided significantly greater clinical improvement following its five-day treatment course, in comparison to treatment with standard of care alone, in the SIMPLE
The CASPIAN trial met the primary endpoint of OS in June 2019, reducing the risk of death by 27% (based on a hazard ratio [HR] of 0.73; 95% confidence
The approval for the Tecentriq, Avastin combination is for unresectable or metastatic HCC patients who did not receive prior systemic therapy. Both the drugs, which already have approvals
Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 (CB1) receptor, which has a known association in renal fibrosis and inflammation. Bird Rock Bio owns the worldwide
As per the terms of the deal, Arcus Biosciences, which is a California-based oncology-focused biopharma company, will get a payment of $375m upon closing from Gilead Sciences. This
With the EC marketing authorization, Zeposia, an oral medication taken once daily, becomes the only approved sphingosine-1-phosphate (S1P) receptor modulator for RRMS patients with active disease. The approval
The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression. This application was reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot
Themis Bioscience is said to have a pipeline of vaccine candidates and immune-modulatory therapies, which have been developed using its measles virus vector platform. In March 2020, the
This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.
In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.